From: Changing monoclonal antibody keeping unaltered the chemotherapy regimen in metastatic colorectal cancer patients: is efficacy maintained?
Overall survival
6 months
12 months
24 months
Median (CI 95%)
p value
ORR
0.02
No
78.6
49.7
11.8
12(9–15)
Yes
100
91.7
55.0
27(11–43)
DCR
52.3
5.3
-
7(5–9)
<0.0001
88.2
33.8
20(15–24)